Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences Journal of Tropical Life Science : International Journal of Theoretical, Experimental, and Applied Life Sciences
Mansur Ibrahim
Brawijaya University
Agriculture, Biological Sciences & Forestry Earth & Planetary Sciences Environmental Science

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Modulation of Granulocyte Cells Development by VipAlbumin® Administration in BALB/C Mice with Diabetes Mellitus Adi Pradana, Andi Rizki; Ibrahim, Mansur; Sasmito Djati, Muhammad; Rifa'i, Muhaimin
Journal of Tropical Life Science Vol 5, No 3 (2015)
Publisher : Journal of Tropical Life Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jtls.05.03.05

Abstract

Diabetes mellitus is a metabolic disease that is caused either by the decrease of insulin secretion frompancreatic β cells or the insensitivity of target cells against insulin. High glucose levels (hyperglycemia condition)can trigger the formation of free radicals, the main cause of diabetes micro and macrovascular complications. Theformation of free radicals and AGE (advanced glycation end-products) is assumed to became the key factor in thedecline of granulocyte cell production as well as the disruption of these cells functional activity. The purpose ofthis research was to determine the role of VipAlbumin® in inhibiting the adverse effects of increased blood glucoselevels, which highly influence the production of granulocyte. This study was divided into in vitro and in vivostage. BALB/C mice were used as experimental animals at in vivo stage and induced to undergo diabetes through100 mg/kg BW streptozotocin (STZ) injection at the age of 5 days. VipAlbumin® administered orally for 14 days,which began when mice reached the age of 14 weeks. The administration of VipAlbumin® divided into 3 dosesi.e. 0,01664 mg/gr BW (1st dose), 0,416 mg/gr BW (2nd dose), and 10,4 mg/gr BW (3rd dose). The further step wasa flowcytometric analysis to see the development of granulocyte cells relative amount, which were isolated fromthe bone marrow. The result of this analysis shows that VipAlbumin® administration, particularly at the 2nd and3rd dose, were able to modulate granulocyte cells development in the bone marrow.
Modulation of Granulocyte Cells Development by VipAlbumin® Administration in BALB/C Mice with Diabetes Mellitus Andi Rizki Adi Pradana; Mansur Ibrahim; Muhammad Sasmito Djati; Muhaimin Rifa'i
Journal of Tropical Life Science Vol. 5 No. 3 (2015)
Publisher : Journal of Tropical Life Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jtls.05.03.05

Abstract

Diabetes mellitus is a metabolic disease that is caused either by the decrease of insulin secretion frompancreatic β cells or the insensitivity of target cells against insulin. High glucose levels (hyperglycemia condition)can trigger the formation of free radicals, the main cause of diabetes micro and macrovascular complications. Theformation of free radicals and AGE (advanced glycation end-products) is assumed to became the key factor in thedecline of granulocyte cell production as well as the disruption of these cells functional activity. The purpose ofthis research was to determine the role of VipAlbumin® in inhibiting the adverse effects of increased blood glucoselevels, which highly influence the production of granulocyte. This study was divided into in vitro and in vivostage. BALB/C mice were used as experimental animals at in vivo stage and induced to undergo diabetes through100 mg/kg BW streptozotocin (STZ) injection at the age of 5 days. VipAlbumin® administered orally for 14 days,which began when mice reached the age of 14 weeks. The administration of VipAlbumin® divided into 3 dosesi.e. 0,01664 mg/gr BW (1st dose), 0,416 mg/gr BW (2nd dose), and 10,4 mg/gr BW (3rd dose). The further step wasa flowcytometric analysis to see the development of granulocyte cells relative amount, which were isolated fromthe bone marrow. The result of this analysis shows that VipAlbumin® administration, particularly at the 2nd and3rd dose, were able to modulate granulocyte cells development in the bone marrow.
Expression of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) in Normal Wistar Rat Post-Cheral® Administration Asyhari, Firda Nuri; Zulfatim, Heni Sukma; Putri, Nenis Try Melani; Dliyauddin, Moh; Jamil, Ahmad Shobrun; Soewondo, Aris; Natsir, Muhammad Halim; Ibrahim, Mansur; Rahayu, Sri; Djati, Muhammad Sasmito; Rifa’i, Muhaimin
HAYATI Journal of Biosciences Vol. 31 No. 5 (2024): September 2024
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.31.5.1030-1036

Abstract

Maintaining immunoglobulin levels in the body is important to protect the body from exposure to pathogens. One effort can be made by consuming herbs containing immunomodulatory compounds, such as Cheral®, which includes a combination of herbs Phyllanthus niruri and Curcuma longa. This research aims to determine the expression of immunoglobulin M (IgM) and immunoglobulin G (IgG) following the administration of Cheral® to Wistar rats. The study was conducted in vivo, utilizing 24 healthy male Wistar rats for a 90-day treatment period. The research was divided into four treatment groups, including a control group and three dosage groups: Dose 1 (156.25 mg/kg BW), Dose 2 (312.5 mg/kg BW), and Dose 3 (468.75 mg/kg BW). IgM and IgG were isolated from the spleen and analyzed using flow cytometry. Flow cytometry data were analyzed using SPSS with a one-way ANOVA and post hoc test (p-value <0.05). The analysis showed that the relative number of IgM-producing cells in the control group was significantly higher than in the treatment groups, with a difference of 44.40%. In contrast, the relative number of IgG-producing cells in Dose 3 was significantly lower than all other treatment groups, showing a decrease of 29.21%. Overall, the expression of IgG and IgM did not differ substantially across all treatments. The lower IgG and IgM profiles compared to the control group indicate Cheral®'s ability to prevent infections and maintain the immune system of the rats throughout the treatment period.
Co-Authors Ahmad Shobrun Jamil Andi Rizki Adi Pradana Andi Rizki Adi Pradana, Andi Rizki Aris Soewondo Asyhari, Firda Nuri Dliyauddin, Moh Moch Sasmito Djati Muhaimin Rifa'i Muhammad Halim Natsir Putri, Nenis Try Melani Rifa'i, Muhaimin Rifa’i, Muhaimin SRI RAHAYU Zulfatim, Heni Sukma